A Long-term Follow-up Study to Evaluate the Injection of EXG102-031 Ophthalmic Injection in Participants With Wet Age-related Macular Degeneration (wAMD).
Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY
This is a long-term, safety and efficacy follow-up study of patients in the EXG102-031-111 gene therapy clinical trial for wAMD. Patients will complete visits from the parent study, and then into this long-term follow-up study for continuous safety monitoring for up to 5 years.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 50
Healthy Volunteers: f
View:
• Previously received treatment with EXG102-031 in the study (EXG102-031-111);
• Paticipantes are informed consent and willingness to follow protocol procedures.
Locations
Other Locations
China
Peking University People's Hospital
RECRUITING
Beijing
Contact Information
Primary
Sara Yang, MD
sarayang@exegenesisbio.com
+86 13957164092
Time Frame
Start Date: 2025-03-13
Estimated Completion Date: 2030-12-01
Participants
Target number of participants: 42
Related Therapeutic Areas
Sponsors
Leads: Hangzhou Jiayin Biotech Ltd
Collaborators: Peking University People's Hospital